Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: a Prespecified Analysis of the STEP-HFpEF Trial
Source : https://pubmed.ncbi.nlm.nih.gov/37952180/
Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life.
In patients with HFpEF and obesity, semaglutide produced large improvements in HF-related symptoms, physical limitations, exercise function, inflammation, body weight and NTproBNP regardless of baseline health status.
Effects of Combined Aerobic Exercise and Diet on Cardiometabolic Health in Patients With Obesity and Type 2 Diabetes: a Systematic Review and Meta-Analysis
Source : https://bmcsportsscimedrehabil.biomedcentral.com/articles/10.1186/s13102-023-00766-5
Lifestyle modifications involving diet and exercise are recommended for patients diagnosed with obesity and type 2 diabetes mellitus (T2DM). The purpose of this review was to systematically evaluate the effects...
The study results indicated that AEDT exerts beneficial changes in body composition, lipid and glucose metabolism, blood pressure, adipose tissue dysfunction, and inflammation in patients with T2DM and concurrent obesity.
Efficacy and Safety of Semaglutide 2.4 mg According to Antidepressant Use at Baseline: a Post Hoc Subgroup Analysis
Source : https://pubmed.ncbi.nlm.nih.gov/37989717/
In adults with overweight/obesity, semaglutide provided clinically meaningful weight loss regardless of baseline AD use, with an AE profile consistent with previous studies.
Regardless of antidepressant use, semaglutide 2.4 mg is an effective treatment option for overweight/obesity, and adverse events are generally similar between placebo and semaglutide 2.4 mg.
The Relation Between Excess Adiposity and Breast Cancer in Women: Clinical Implications and Management
Source : https://www.sciencedirect.com/science/article/pii/S1040842823003013?via=ihub
Breast cancer (BC) is the most common cancer in women. While the combination of improved screening, earlier detection, and advances in therapeutics ha...
Weight gain prevention and weight loss interventions should ideally be seamlessly included in the management of BC to provide a holistic, individualized approach to improve health and survival in this population.
Semaglutide and Tirzepatide Reduce Alcohol Consumption in Individuals With Obesity
Source : https://www.nature.com/articles/s41598-023-48267-2
Alcohol Use Disorder (AUD) contributes significantly to global mortality. GLP-1 (Glucagon-like peptide-1) and GLP-1/GIP (Glucose-dependent Insulinotropic Polypeptide) agonists, FDA-approved for managing type 2 diabetes and obesity, where the former has...
Researchers observed a reduction in average number of drinks, binge drinking, AUDIT score, and the sedative/stimulating effects of alcohol in individuals taking semaglutide or tirzepatide.